Compare SSBI & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SSBI | CING |
|---|---|---|
| Founded | 1982 | 2012 |
| Country | United States | United States |
| Employees | 106 | 13 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.7M | 93.1M |
| IPO Year | N/A | N/A |
| Metric | SSBI | CING |
|---|---|---|
| Price | $13.02 | $7.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $37.00 |
| AVG Volume (30 Days) | 3.6K | ★ 526.0K |
| Earning Date | 04-28-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.23 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.60 | $3.20 |
| 52 Week High | $14.00 | $11.89 |
| Indicator | SSBI | CING |
|---|---|---|
| Relative Strength Index (RSI) | 47.68 | 49.96 |
| Support Level | $12.73 | $3.62 |
| Resistance Level | $13.95 | $7.92 |
| Average True Range (ATR) | 0.25 | 1.01 |
| MACD | -0.03 | 0.10 |
| Stochastic Oscillator | 32.53 | 25.59 |
Summit State Bank provides various banking products and services to individuals and businesses in Sonoma County, California. It offers personal and business checking, money market, sweep, savings, and demand accounts; time certificates of deposit; and specialized deposit accounts, such as professional, small business packaged, tiered, and retirement plan accounts. The company also provides loans, including commercial loans and leases; lines of credit; commercial real estate, small business administration, residential mortgage, and construction loans; home equity lines of credit; and term and equipment loans, as well as loans to agriculture-related businesses.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.